TCT 2021 | SUGAR Trial: Polymer-Free Stent in Diabetes

In CAD patients with diabetes the polymer-free amphilimus-eluting stent resulted non-inferior to the polymer-based zotarolimus-eluting Resolute Onyx.

TCT 2021 | SUGAR Trial: Stent libre de polímero en diabetes

This new device, in addition to ultrathin struts, has already been found non-inferior to the Resolute Integrity in the general population at 3-year followup. Researchers believe that the new amphiphilic carrier might be especially useful in diabetic patients given its greater diffusion along the arterial walls. 

This hypothesis has generated the present study called SUGAR, presented in the scientific sessions at TCT 2021 and simultaneously published in the European Heart Journal.

The new device compared against the Resolute Onyx has shown 35% relative risk reduction of the combined end point (p<0.0001 for non-inferiority). An exploratory analysis has even shown superiority (p=0.03).

Despite these results, the authors still admit to the Onyx’s capacity to go through calcified, tortuous, or long lesions. 

The SUGAR included 1175 diabetic patients with no clinical presentation, complexity, or lesion number limitation. The study even included patients with left main lesion. Half of these patients have multivessel disease. 


Read also: AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?


586 patients were randomized to receiving the Cre 8 EVO (this new device) and 589 to receiving Resolute Onyx.

After one-year followup, target vessel failure rate resulted 7.2% for the Cre8 EVO vs 10.9% for Onyx.

The advantage was mainly driven by revascularization as of 7 or 8 months in the Onyx arm.


Read also: Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?


Even though the evidence is quite compelling, we still have a long way to go before considering this the new standard for diabetics. 

libre-de-polímero-en-DBT

Original Title: Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial).

Reference: Rafael Romaguera et al. Eur Heart J. 2021 Nov 4;ehab790. Online ahead of print. doi: 10.1093/eurheartj/ehab790. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....